EUVIMEDEUVIMED entdecken
Crossref

Discovery of novel potent PI3K/mTOR dual‐target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity

Yang Yang, Xin Sun, Leixuan Luo, Rujue Peng, Ruiqing Yang, Zhenjie Cheng, Yao Lv, Hongfeng Li, Qidong Tang, Wufu Zhu, Dan Qiao, Shan Xu

Archiv der Pharmazie · 2023-12 · 356 (12)

DOI: 10.1002/ardp.202300403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 15.10.2023. Verfasst von Yang Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang, China. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinases, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangxi, China, Science and Technology Project Founded by the Education Department of Jiangxi Province, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The PI3K/AKT/mTOR pathway is one of the most common dysregulated signaling cascade responses in human cancers, playing a crucial role in cell proliferation and angiogenesis. Therefore, the development of anticancer drugs targeting the PI3K and mTOR pathways has become a research hotspot in cancer treatment. In this study, the PI3K selective inhibitor GDC‐0941 was selected as a lead compound, and 28 thiophenyl‐triazine derivatives with aromatic urea structures were synthesized based on scaffold hopping, serving as a novel class of PI3K/mTOR dual inhibitors. The most promising compound Y‐2 was obtained through antiproliferative activity evaluation, kinase inhibition, and toxicity assays. The results showed that Y‐2 demonstrated potential inhibitory effects on both PI3K kinase and mTOR kinase, with IC 50 values of 171.4 and 10.2 nM, respectively. The inhibitory effect of Y‐2 on mTOR kinase was 52 times greater than that of the positive drug GDC‐0941. Subsequently, the antitumor activity of Y‐2 was verified through pharmacological experiments such as AO staining, cell apoptosis, scratch assays, and cell colony formation. The antitumor mechanism of Y‐2 was further investigated through JC‐1 experiments, real‐time quantitative PCR, and Western blot analysis. Based on the above experiments, Y‐2 can be identified as a potent PI3K/mTOR dual inhibitor for cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphatidylinositol 3-KinasesAntineoplastic AgentsHumansMTOR InhibitorsStructure-Activity RelationshipTOR Serine-Threonine KinasesPhosphoinositide-3 Kinase InhibitorsCell ProliferationProtein Kinase InhibitorsCell Line, TumorProto-Oncogene Proteins c-aktApoptosisIndazolesSulfonamides

Stichwörter der Autor:innen

PI3K/AKT/mTOR pathwayanticancerantiproliferative activitydual PI3k/mTOR inhibitor

Substanzen

Phosphatidylinositol 3-KinasesMTOR InhibitorsTOR Serine-Threonine KinasesAntineoplastic AgentsPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins c-akt2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidineIndazolesSulfonamides

Autor:innen und Institutionen

  • Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang, China.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangxi, China
  • Science and Technology Project Founded by the Education Department of Jiangxi Province, China
  • Outstanding youth Foundation Program Jiangxi Province, China

Zitieren

APA

Yang, Y., Sun, X., Luo, L., Peng, R., Yang, R., Cheng, Z., Lv, Y., Li, H., Tang, Q., Zhu, W., Qiao, D., & Xu, S. (2023). Discovery of novel potent PI3K/mTOR dual‐target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity. Archiv der Pharmazie, 356(12). https://doi.org/10.1002/ardp.202300403

Vancouver

Yang Y, Sun X, Luo L, Peng R, Yang R, Cheng Z, et al. Discovery of novel potent PI3K/mTOR dual‐target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity. Archiv der Pharmazie. 2023;356(12). doi:10.1002/ardp.202300403

BibTeX
@article{Yang2023,
  author = {Yang, Yang and Sun, Xin and Luo, Leixuan and Peng, Rujue and Yang, Ruiqing and Cheng, Zhenjie and Lv, Yao and Li, Hongfeng and Tang, Qidong and Zhu, Wufu and Qiao, Dan and Xu, Shan},
  title = {Discovery of novel potent PI3K/mTOR dual‐target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity},
  journal = {Archiv der Pharmazie},
  year = {2023},
  volume = {356},
  number = {12},
  doi = {10.1002/ardp.202300403}
}
Kostenlos starten →